www.nephjc.com
www.nephjc.com/newsl...
www.nephjc.com/newsl...
Bottomline?
In ICD patients with mildโmoderate CKD, raising plasma K safely cut arrhythmias, HF/arrhythmia hospitalizations, and death
But is it practice-changingโฆ or still a โwait and seeโ? ๐ค#NephJC
Bottomline?
In ICD patients with mildโmoderate CKD, raising plasma K safely cut arrhythmias, HF/arrhythmia hospitalizations, and death
But is it practice-changingโฆ or still a โwait and seeโ? ๐ค#NephJC
โ Strengths: Strong recruitment, adjudicated endpoints
โ ๏ธLimitations: Single country, ICD-only patients, eGFR <30 excluded, <50% reached Kโบ target, unclear separation of MRA vs Kโบ effects #NephJC
โ Strengths: Strong recruitment, adjudicated endpoints
โ ๏ธLimitations: Single country, ICD-only patients, eGFR <30 excluded, <50% reached Kโบ target, unclear separation of MRA vs Kโบ effects #NephJC
POTCAST interventions are widely available
๐ diet
๐ MRAs
๐ง KCl supplements
๐ง reducing Kโบ-losing diuretics
<50% hit the target but ~75% stayed on therapyโฆ enough to improve outcomes #NephJC
POTCAST interventions are widely available
๐ diet
๐ MRAs
๐ง KCl supplements
๐ง reducing Kโบ-losing diuretics
<50% hit the target but ~75% stayed on therapyโฆ enough to improve outcomes #NephJC
T3k
If K is the answer for arrhythmias, maybe itโs time to rethink โnormalโ ranges for high-risk patients Hyperkalemia risk exists in those w/ CKD but careful monitoring keeps high-normal K safe-ish #NephJC
T3k
If K is the answer for arrhythmias, maybe itโs time to rethink โnormalโ ranges for high-risk patients Hyperkalemia risk exists in those w/ CKD but careful monitoring keeps high-normal K safe-ish #NephJC
Could the benefits of ACEi/ARBs, ARNIs, MRAs, and beta-blockers be partly just potassium doing its thing?
They do nudge Kโบ up a bitโฆ
Letโs hear your thoughts ๐ญ #NephJC
Could the benefits of ACEi/ARBs, ARNIs, MRAs, and beta-blockers be partly just potassium doing its thing?
They do nudge Kโบ up a bitโฆ
Letโs hear your thoughts ๐ญ #NephJC
It seems like nephrologists are somehow quietly saving cardiology
And yes, Iโm talking about the pillars of HF management ๐๐#NephJC
It seems like nephrologists are somehow quietly saving cardiology
And yes, Iโm talking about the pillars of HF management ๐๐#NephJC
Interestingly, benefits werenโt limited to HF patients
๐~40% of participants without HF also showed improved outcomes!
And potassium may be the unifying mechanism ๐ฅ#NephJC
Interestingly, benefits werenโt limited to HF patients
๐~40% of participants without HF also showed improved outcomes!
And potassium may be the unifying mechanism ๐ฅ#NephJC
Traditionally, this K rise was seen as a side effect, needing close observation and possible intervention,
but POTCAST suggests it might actually contribute to the benefit #NephJC
Traditionally, this K rise was seen as a side effect, needing close observation and possible intervention,
but POTCAST suggests it might actually contribute to the benefit #NephJC
In the landmark MRA trials (RALES, EPHESUS, EMPHASIS-HF, FINEARTS-HF), patients taking MRAs for HF had improved survival, including fewer sudden cardiac deaths #NephJC
In the landmark MRA trials (RALES, EPHESUS, EMPHASIS-HF, FINEARTS-HF), patients taking MRAs for HF had improved survival, including fewer sudden cardiac deaths #NephJC
POTCAST showed us that this modest increase translated into:
โ ๏ธfewer arrhythmias, hospitalizations, and deathsโฆ
And this is despite less than half of participants reaching the exact target.
So what is the exact target? #NephJC
POTCAST showed us that this modest increase translated into:
โ ๏ธfewer arrhythmias, hospitalizations, and deathsโฆ
And this is despite less than half of participants reaching the exact target.
So what is the exact target? #NephJC
This study show us that physiology supports a rise from 4.0 to 4.3 mmol/L which leads to:
โกFewer hypokalemia episodes
๐ซStabilized resting potential
๐Fewer ICD shocks & arrhythmias #NephJC
This study show us that physiology supports a rise from 4.0 to 4.3 mmol/L which leads to:
โกFewer hypokalemia episodes
๐ซStabilized resting potential
๐Fewer ICD shocks & arrhythmias #NephJC
Most of the benefit came from fewer ICD therapies (shocks or pacing) and documented ventricular tachycardia. Effects were consistent across subgroups & independent of the drug used #NephJC
Most of the benefit came from fewer ICD therapies (shocks or pacing) and documented ventricular tachycardia. Effects were consistent across subgroups & independent of the drug used #NephJC
Most of the benefit came from fewer ICD therapies (shocks or pacing) and documented ventricular tachycardia. Effects were consistent across subgroups & independent of the drug used #NephJC
Most of the benefit came from fewer ICD therapies (shocks or pacing) and documented ventricular tachycardia. Effects were consistent across subgroups & independent of the drug used #NephJC
This study suggests that a small dietary & treatment-induced increase in Kโบ (~0.3 mmol/L) lowered the risk of arrhythmias, ICD therapy, CV hospitalizations, and death in high-risk ICD patients #NephJC
This study suggests that a small dietary & treatment-induced increase in Kโบ (~0.3 mmol/L) lowered the risk of arrhythmias, ICD therapy, CV hospitalizations, and death in high-risk ICD patients #NephJC
Feeling the K rush? Weโve charged through the resultsโฆ now letโs talk
Is aiming for high-normal potassium the real shock therapy for arrhythmias? #NephJC
Feeling the K rush? Weโve charged through the resultsโฆ now letโs talk
Is aiming for high-normal potassium the real shock therapy for arrhythmias? #NephJC
Discontinuations: 67 participants stopped meds due to side effects:
โ ๏ธ 27% MRA
โ ๏ธ 34% Kโบ supplements
โ ๏ธ 39% both
Although, the side effects were manageable #NephJC
Discontinuations: 67 participants stopped meds due to side effects:
โ ๏ธ 27% MRA
โ ๏ธ 34% Kโบ supplements
โ ๏ธ 39% both
Although, the side effects were manageable #NephJC
Only 41.5% reached the target 4.5โ5.0 mmol/L
Reasons: max dose reached, declined meds, protocol limits, or other factors
๐Mean Kโบ rose to 4.36 mmol/L, a difference of only 0.3 treatment vs control
Is it really Kโบ driving the results? #NephJC
Only 41.5% reached the target 4.5โ5.0 mmol/L
Reasons: max dose reached, declined meds, protocol limits, or other factors
๐Mean Kโบ rose to 4.36 mmol/L, a difference of only 0.3 treatment vs control
Is it really Kโบ driving the results? #NephJC